ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

AstraZeneca Breaks With Targacept

by Lisa M. Jarvis
October 20, 2014 | APPEARED IN VOLUME 92, ISSUE 42

AstraZeneca is pulling the plug on its long-term relationship with Targacept. The companies first partnered in late 2005 to develop molecules that modulate neuronal nicotinic receptors, but over the years they expanded their pact to include other types of drug candidates, all of which have failed. AstraZeneca’s biggest commitment came in 2009, when it shelled out $200 million for the rights to TC-5214, a treatment for major depressive disorder. The big pharma firm handed TC-5214 back to Targacept in 2012 after a failed Phase III study.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment